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significant predictor of CV death (hazard ratio [HR] 2.26, 95% Cl 1.78.2.86), fatallnon- 
fatal MI (HR 2.16, 95% Cl 1.67.2.80), fatal/non-fatal stroke (HR 1.76, 95% Cl 1.39-2.21) 
and the composite CV endpoint (HR 1.99, 95% Cl 1.70-2.33). In Cox multivariate analy- 
ses controlling for age, gender, race, diabetes. history of ischemic heart disease, con- 
gestive heart failure, stroke, or peripheral vascular disease, baseline albuminlcreatinine 
ratio, Systolic and diastolic blood pressure, baseline Cornell product and Sokolow-Lyon 
voltage, and for the impact of treatment with losarian vs atenolol on CV outcomes, ECG 
strain remained a significant predIctor of CV mortality (HR 1.53, 95% Cl 1.16.2.00), Ml 
(HR 1.55, 95% Cl 1.16-2.06) and of the composite CV endpoint (HR 1.33, 95% Cl 1.11. 
1.59). 
Conclusions: ECG strain IS a marker of Increased CV nsk in hypertensive patients I” the 
setting of aggressive blood pressure lowering. Serial assessment of lateral ST segment 
and T-wave findings may prove to be useful in further stratifying nsk and identifying 
patients who may require additional antihypertensive therapy. 
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1079-l 26 Increased CD40 Ligand, C-Reactive Protein, and 
Platelet-Monocyte Binding in Patients With Type 1 
Diabetes Mellitus 
Scoff A. Harding Andrew J. Sommerfield, Jaydeep Sarma, Patrick J. Twomey, David E. 
Newby. Brian M. Frier, Ketth A. A. Fox, Royal Infirmary of Edinburgh, Edmburgh, United 
Kingdom 
Background: Patients with type I diabetes mellltus have a markedly increased nsk of 
developing cardiovascular disease. The CD40-CD40 ligand (L) dyad and platelat-mono- 
cyte bindlng (PMB) may play an Important role in atherogenesis, plaque rupture and 
thrombosis. We hypothesized that patients with uncomplicated type I diabetes mellitus 
would demonstrate altered CD40L expression and PM0 in keeping with a pro-inflamma- 
tory state. 
Methods: Twenty-two patients with type I diabetes without clinical evidence of vascular 
disease, hypertension or nephropathy were compared to 22 age- and sex-matched 
healthy control subjects. All subjects were non-smokers and mamtained on no medica- 
tions except insulin. Serum concentrations of soluble (s) CD40L and C-reactive protein 
(CRP) were determined by ELISA and an ultra-sensitive latex enhanced Immunoturbidi- 
metric assay respectively. PM6 and surface expression of CD40L on platelets were 
assessed by flow cytometry. lsotype control monoclonal antibodies were used to estab- 
lish baseline fluorescence above which all events ware deemed positive. 
Results: Baselme characteristics including age, sex, body mass index, total cholesterol 
and HDL cholesterol were similar between the groups. Patients with type I diabetes com- 
pared with non-diabetic controls, have higher serum concentrations of CRP (0.33 f 0.09 
mgldl vs. 0.1 * 0.02 mgldl, p=O.Ol) and soluble CD40L (10.0 * 1.4 nglml vs. 4.6 * 0.6 ngl 
ml, p=O.O06). Patients with type I diabetes mellitus also had higher platelet expression of 
CD40L (13.8 f. 0.9% vs. 6.5 + 1.1% pcO.001) and PM6 (35.9 + 3.3% VS. 26.4 * 2.9%, 
p=O.OOS). Borh sCD4OL (r=0.34, p=O.O3) and platelet surface expression of CD40L 
(r=0.56, pcO.001) were positively correlated with HbAlc but not CRP. In contrast, PMB 
was positively correlated with CRP (r=0.46, p=O.O2) but not HbAlc. 
Conclusions: Despite the absence of clinical vascular disease, patlents with uncompll- 
cated type I diabetes mellitus have evidence of systemic inflammation that is associated 
with platelet activation. These findings provide novel insights that may help explain the 
susceptibility of patients with type I diabetes mellltus to the development of cardiovascu- 
lar disease. 
1079-127 The 4G15G Promotor Polymorphism of the PAI- Gene Is 
Associated With Coronary Artery Disease and Linked to 
the HINDIll Polymorphism 
Jens D. Lohrmann, Tobias Krauss, Karlheinz Peter, Christoph Bode, Burton E. Sobel, 
Thomas K. Nordt, University of Freiburg, Freiburg, Germany, University of Vermont 
College of Medicine, Burlington, VT 
Background: Increased actlwty of plasminogen activator Inhibitor type-l (PAI-1) is an 
independent risk factor for coronary artery disease (CAD). The 4Gi5G polymorphism in 
the promotor of the PAI-I gene influences PAI- expresston with carriers of the 4G allele 
exhibiting higher plasma levels of PAI-1. For the Hindlll polymorphism located at the 3 
end of the PAI- gene an association with CAD has been described for bofh homozygous 
genotypes (l/l and Z/2) The study was designed lo compare the predictive power of 
both polymorphisms with respect to CAD. 
Methods: 112 patients with CAD who underwent percutaneous coronary intervention and 
44 healthy controls were genotyped by restrictic ) fragment length polymorphism analysis 
for the 4G/5G and the Hindlll genotypes. 
Results: 41 (37%) patients were genotyped 4G/4G, 56 (50%) were 4G/5G, and 15 (13%) 
5G/5G (allele frequency 4G: 0.62; 5G: 0.38). Results in controls were 9 (20%) 4G/4G, 25 
(57%) 4G/5G, and 10 (23%) 5G/5G, respectively (allele frequency 4G: 0.49; 5G: 0.51), 
with a statistically significant higher frequency of the 4G allele in patients (p=O.O27). In 
contrast, there was no significant difference in the distribution of the Hindlll genotypes 
between patients and controls: 26 (23%) were genotyped l/l, 52 (47%) l/Z, and 34 
(30%) 212 (allele frequency 1: 0.46; 2: 0.54). 9 (20%) controls were genotyped l/l, 20 
(46%) l/2, and 15 (34%) Z2 (allele frequency 1: 0.43; 2: 0.57). Considering possible link- 
age between both polymorphisms, in patients the occurrence of the 5Gl5G genotype was 
restricted lo the 212 genotype (n=l5) while the l/l genotype cumulated among carriers of 
the 4G/4G genotype (n=26) with similar findings in the control group. Statistical analysis 
revealed a strong linkage of the 2 allele with fhe 5G allele and of the 1 allele with the 4G 
allele both in patlents (pcO.01) and in controls (p= 0,033). 
Conclusions: The 4Gl5G and the Hindlll polymorphism in the PAI- gene exhibit strong 
linkage. The 4Gl5G polymorphism has a higher predictive power for CAD, making it more 
suitable for estimation of the risk for CAD. 
1079-l 28 Influence of CYPZC9 Polymorphism on Fluindione Dose 
Requirement and Anticoagulation 
Katv Dldier, Laurent Bermont, Nicolas Meneveau, Bernard Royer, Chnstiane Mougin, 
Jean-Pierre L. Bassand, Francois Schiele, University Hospital Jean-Minjoz. Besancon, 
France 
Background:Fluindione, an anticoagulant of the lndanedlone family, requires careful 
management because of indlvldual variability and genetlc susceptibility. The hepatic 
cytochrome CYPPCS IS the principal enzyme involved in the coumarinic family metabo- 
lism and its 2 variants, CYP2C9’2 and CYP2C9’3, are associated with lower dose 
requirementHowever, the metabolic pathway of Flulndione degradation is not known. 
0bjective:To determine the influence of CYP2C9.2 and CYP2C9’3 variants on dose 
requirement and anticoagulation status I” a population of Fluindtone-treated patients. 
Methods: From May to August 2002, genotyping for the CYP2C9’2 and CYP2C9’3 alle- 
les was done by Polymerase Chain Reaction (PCR). INR and Fluindlone dose were 
noted at discharge and for one month. 
Results:01 40 patients with analysable data. 24(60%) had the wild-type (*l/*1) genotype, 
11(27.5%) the heterozygote C2(‘11^2). 3(7.5%) the heterozygote C3(‘li*3), 1(2.5%) the 
heterozygote C2C3(‘2/*3)and 1(2.5%) the homozygote C3(‘3/*3) genotype. 
Carriers of C2C3 or C3C3 variants required a significantly lower dose of Fluindlone and 
had a significantly higher INR compared to carriers of other variants. 
Conclus~on:Our results suggest that the CYP2C9 polymorphism is associated with a 
lower dose requirement and with over-anticoagulation. Thus, the CYP2C9 could be impll- 
cated in the Flumdione metabolism. 
1079-129 Genotype-Dependent Inhibition of PAI-I Expression in 
Human Vascular Smooth Muscle Cells by PPAR-Gamma 
Agonists 
Thomas K. Nordt, Sandra Ernst, Yabing Chen, David J. Schneider, Christoph Bode, 
Burton E. Sobel, University of Freiburg. Fretburg, Germany, University of Vermont 
College of Msdlcine, Burlington, VT 
Background: The PPAR-7 agonist troglitazone has recently been shown to reduce the 
expression of PAI-1 in human vascular smooth muscle cells (HVSMC). In the present 
study we sought to determlne whether this effect is a class or a agent specific one and 
whether it is dependant on the 4G/5G polymorphism in the promoter of the PAI- gene. 
Methods and results: HVSMC under basal and stimulated (40 pM TGF-P) conditions 
were incubated with selected concentrations (0, 1, 3.3, 10 nM) of glitazones for 24 h. 
PAI- protein concentration in conditioned media (ELISA) was not significantly affected 
by glitazones under basal conditions. In contrast, under stimulated conditions, PAI- 
expression decreased by 56t4% (mean*SEM) with troglitazone (p&002) and by 
63~22% with ciglitazone (p=O.O27). Rosiglitazone tended to decrease PAI- expression 
by 25*18% (p=ns), pioglitazone was without effect (n=3, each in triplicate). The inhibitory 
effect of tro- and ciglitazone persisted for up to 72 h. Total protein synthesis was not 
affected by glitazones suggesting their specific action. The concomitiant expose of cells 
to insulin did not affect the inhibition of PAI- expression by glitazones (also known as 
insulin sensitizers. n=6). PAI- gene expression (RT-PCR) was affected accordingly 
(1x4). HVSMC were genotyped with respect to the 4Gi5G polymorphism and CHO cells 
were transfected with plasmids containing either the 4G or the 5G genotype of the PAI- 
promoter as well as luciferase as reporter gene. In HVSMC (n=29 donors) with genotype 
4Gi4G troglitazone reduced PAI- expresston by 29-t16%, in those with 5GI5G by 
58+17% (p=O.O28). In CHO (n=l3 transfections) a corresponding reduction was obtained 
(p=ns). 
Conclusions: Dlfferent glltazones at pharmacological concentrations Inhibit PAI- expres- 
sion I” HVSMC to substantially different extents. The 5G allele of the 4GiSG polymor- 
phism is more susceptible to Inhibition by troglitazone than the 4G allele. Thus, the 
selection of gliiazone and the PAI- genotype seem to be of pharmacodynamic and of 
pharmocogenetic relevance with respect to normalizing pathologically increased PAI- 
expression. 
